Bloomberg Anywhere Login


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

Last $46.67 USD
Change Today +0.41 / 0.89%
Volume 752.8K
NBIX On Other Exchanges
As of 8:10 PM 08/28/15 All times are local (Market data is delayed by at least 15 minutes).

Executive Profile*

Kevin C. Gorman Ph.D.

Chief Executive Officer, President and Director,Neurocrine Biosciences Inc.
AgeTotal Calculated CompensationThis person is connected to 7 board members in 1 different organizations across 1 different industries.

See Board Relationships
As of Fiscal Year 2014


Dr. Kevin C. Gorman, Ph.D. has been Chief Executive Officer and President of Neurocrine Biosciences Inc., since January 2008. Dr. Gorman is responsible for the in-licensing and out-licensing of technologies and products, corporate partnering activities and strategic planning. He served as Chief Business Officer and Executive Vice President of Neurocrine Biosciences Inc. since January 2006 and also served as its Chief Operating Officer since September 2006. He served ...

Read Full Background

Corporate Headquarters*

12780 El Camino Real
San Diego, California 92130

United States

Phone: 858-617-7600
Fax: 858-617-7602

Board Members Memberships*

Chief Executive Officer, President and Director


University of California-Los Angeles
University of California-Los Angeles
Post-Doctoral Training
Rockefeller University

Other Affiliations*

Annual Compensation*

Total Annual Compensation$958,556

Stock Options*

Restricted Stock Awards$2,546,700
All Other Compensation$39,596
Exercised Options178,000
Exercised Options Value$1,917,065
Exercisable Options708,952
Exercisable Options Value$10,957,176
Unexercisable Options291,048
Unexercisable Options Value$2,508,024
Total Value of Options$15,382,265
Total Number of Options1,178,000

Total Compensation*

Total Annual Cash Compensation$998,152
Total Short Term Compensation$958,556
Other Long Term Compensation$2,586,296
Total Calculated Compensation$5,952,852
*Data is at least as current as the most recent Definitive Proxy.

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
NBIX:US $46.67 USD +0.41


Ian C. Read Chairman, Chief Executive Officer and Chairman of Executive Committee
Pfizer Inc.
Olivier Brandicourt Chief Executive Officer and Director
Christophe Weber Chief Executive Officer, President and Representative Director
Takeda Pharmaceutical Company Limited
Compensation as of Fiscal Year 2014.

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact NEUROCRINE BIOSCIENCES INC, please visit . Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at